Once enabled, Claude gains access to a private computer environment where it can write code and run programs to create the files you need. This represents a significant expansion ...
Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.